{
    "id": 419,
    "fullName": "ASXL1 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type ASXL1 indicates that no mutation has been detected within the ASXL1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 171023,
        "geneSymbol": "ASXL1",
        "terms": [
            "ASXL1",
            "BOPS",
            "MDS"
        ]
    },
    "variant": "wild-type",
    "createDate": "04/24/2014",
    "updateDate": "07/13/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6169,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).",
            "molecularProfile": {
                "id": 22786,
                "profileName": "ASXL1 wild-type TET2 mut"
            },
            "therapy": {
                "id": 651,
                "therapyName": "Azacitidine",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3740,
                    "pubMedId": 25224413,
                    "title": "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25224413"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6170,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).",
            "molecularProfile": {
                "id": 22786,
                "profileName": "ASXL1 wild-type TET2 mut"
            },
            "therapy": {
                "id": 650,
                "therapyName": "Decitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3740,
                    "pubMedId": 25224413,
                    "title": "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25224413"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13713,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 29393,
                "profileName": "ASXL1 wild-type CALR mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 512,
            "profileName": "ASXL1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22786,
            "profileName": "ASXL1 wild-type TET2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29393,
            "profileName": "ASXL1 wild-type CALR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29396,
            "profileName": "ASXL1 wild-type CALR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}